Oppenheimer Lowers Rain Oncology (NASDAQ:RAIN) to Market Perform

Oppenheimer lowered shares of Rain Oncology (NASDAQ:RAIN – Get Rating) from an outperform rating to a market perform rating in a research report report published on Monday, The Fly reports. A number of other equities research analysts also recently issued reports on the stock. Mizuho decreased their price target on shares of Rain Oncology from […]

Related Keywords

United States ,Piper Sandler ,Monashee Investment Management ,Citigroup ,Capital Corp ,Rain Therapeutics Inc ,Rain Oncology Company Profile ,Boxer Capital Llc ,Goldman Sachs Group Inc ,Sectoral Asset Management Inc ,Rain Oncology ,Get Rating ,Oncology Stock Down ,Boxer Capital ,Asset Management ,Investment Management ,Goldman Sachs Group ,Sachs Group ,Therapeutics Inc ,Rain Oncology Daily ,Nasdaq Rain ,Rain ,Medical ,Downgrade ,Oppenheimer Holdings Inc ,